Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms, working in AI-powered disease detection and intelligent care coordination, today announced that it has signed an exclusive agreement with the University of California, San Francisco (UCSF) to commercialize three AI algorithms for the automated detection of cardiovascular diseases. Developed at UCSF by leading researchers, these AI algorithms to detect cardiac amyloidosis, pulmonary hypertension, and supraventricular tachycardia are based on the analysis of electrocardiograms (ECGs), the most widely used diagnostic test for the characterization of cardiac structure and electrical activity of the heart.

“We are enthusiastic about the possibility of applying these AI-powered algorithms in clinical practice to enable knowledge and discovery, and to provide timely insights for decision-making,” said Anthony Francis, executive director of the Office of Technology Management and Advancement from the University. ”These algorithms improve on existing systems and meet or exceed clinically accepted standards of care.”

Assistant Professor Geoff Tison, PhD. is a principal researcher at UCSF whose work was the basis for this agreement.